Some recent analyst ratings include

• 11/19/2019-
  Allergan plc (NYSE:AGN) gets downgraded to Neutral by UBS Group with a price target of $203.00
• 9/30/2019-
  Allergan plc (NYSE:AGN) had its Outperform rating reiterated by Wells Fargo & Co with a $184.00 price target
• 8/8/2019-
  Allergan plc (NYSE:AGN) had its Hold rating reiterated by Royal Bank of Canada with a $178.00 price target
• 8/7/2019-
  Allergan plc (NYSE:AGN) gets downgraded to Neutral by Guggenheim
• 7/18/2019-
  Allergan plc (NYSE:AGN) had its Outperform ➝ Market Perform rating reiterated by Svb Leerink with a $188.00 price target

• On 3/7/2019 Brent L Saunders, Chairman, bought 1,760 with an average share price of $143.67 per share and the total transaction amounting to $252,859.20.
• On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
• On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
• On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
• On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
• On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
• On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.

Recent Trading Activity for